Since 2008, FarmaSino Group has grown into a comprehensive biopharmaceutical international enterprise, built on a foundation of integrated research, development, production, and global trade. We provide a seamless, end-to-end supply chain across three core pillars: Active Pharmaceutical Ingredients (APIs), Contract Manufacturing of Finished Pharmaceutical Formulations (FDFs), and Advanced Medical Devices.
Our structure, comprising eight wholly-owned subsidiaries, allows for specialized expertise at every stage. From dedicated R&D centers like SkyRun Pharma, focused on innovative drug development, to large-scale, cGMP-compliant production bases in Jiangsu and Anhui, we control for quality and efficiency. This vertical integration is your strategic advantage, offering a single, reliable partner for complex B2B sourcing needs, CDMO services, and MAH development.
We are a trusted partner to over 1,000 enterprise clients across the globe, with significant market presence in South America, Western Europe, the Middle East, and Southeast Asia. Our unwavering commitment to global quality standards is demonstrated by our CNAS accreditation, ISO 9001, ISO 13485, and CE marking. Our manufacturing facilities are also FDA registered. We navigate the complexities of international compliance with our dedicated Regulatory Affairs team, ensuring our products are ready for your markets. For procurement leaders seeking reliability, scalability, and a partner vested in quality, FarmaSino Group delivers. We bridge the gap between innovation and stable supply, empowering better health worldwide. Partner with us for reliable, high-quality sourcing—contact our global team today.
Our capabilities and stability, at a glance. We are built for partnership.
Demonstrating financial stability and partner trust in our scalable supply chain.
Deep experience navigating regulatory and logistics complexities in the Africa, EU, Americas, and Asia-Pacific.
Offering a comprehensive range across APIs, pharmaceuticals, and medical devices to simplify your sourcing.
A network of specialized centers for R&D, API production, finished formulations, and medical devices.
Driving efficient, customized production and dedicated R&D for our global clients.
Our facilities operate under strict cGMP and ISO guidelines, ensuring auditable, compliant products.
As a leading global manufacturing partner, we provide comprehensive contract manufacturing services across Rx formulations, OTC consumer health, and nutritional supplements. Operating advanced, cGMP-compliant facilities, we offer large-scale production capacity for diverse dosage forms, including tablets, softgels, and liquids. Our dual-track manufacturing ecosystem ensures effective segregation and quality consistency, supported by global regulatory credentials such as TGA clearance and USDMF filings. From formulation development to commercial scale-up, we deliver compliant, market-ready solutions for pharmaceutical brand owners and healthcare companies worldwide.
Through our FarmaMed division, we provide a growing portfolio of innovative medical devices and diagnostics. This strategic expansion complements our pharmaceutical offerings, allowing our procurement partners to consolidate sourcing. From diagnostic R&D at Health Port Biotech to globally-marketed devices, we prioritize quality and usability, ensuring our products strictly comply with international regulatory standards.
Our group's R&D engine, led by specialized subsidiaries like SkyRun Pharma, drives innovation in API development. We offer comprehensive CDMO services, from route scouting and process optimization to commercial scale-up. Our teams, with over 15 years of industry experience, specialize in complex synthesis across key therapeutic areas—including Anti-infectives and Oncology—ensuring a robust pipeline and reliable supply for our global pharmaceutical partners.
Our global footprint is supported by a robust logistics and trade infrastructure, including our trading hub in Hong Kong, China. Exporting 80-90% of our production to over 1,000 clients across Africa, the EU, the Americas, and Asia-Pacific, we are a proven partner for scalable supply. Our annual sales exceeding $200M reflect the trust partners place in our ability to consistently deliver high-volume, compliant products on time.
A milestone year marking sales over 1 Billion RMB and the launch of our dedicated R&D engine, SkyRun Pharma Co., Ltd.
Our history is one of strategic, integrated growth. We have deliberately built our capabilities to become a complete solutions provider for our global partners.
FarmaSino Co., Ltd. is founded, alongside our first production center, Anhui Sino Pharmaceutical, establishing our integrated vision from day one.
We expand our global trade capabilities with the establishment of FarmaSino Holdings (HK) Co., Ltd. to better serve our international clients.
A milestone year marking sales over 1 Billion RMB and the launch of our dedicated R&D engine, SkyRun Pharma Co., Ltd.
Strategic growth continues with the acquisition of Zonta Pharma Co., Ltd., strengthening our manufacturing portfolio.
We significantly scale our capacity by establishing a new 300-acre API base (FarmaSino Pharmaceuticals - Anhui) and launching our FarmaMed (Farmasino Medical Co.,Ltd) medical device division.
Our commitment to world-class quality is formally recognized with CNAS accreditation, as group sales surpass $200 Million USD.
We continue to enhance our R&D, acquiring Health Port Biotech to expand our diagnostic capabilities. Our vision is focused on sustainable growth and deepening our role as a trusted global healthcare partner.
Be the first to get our latest styles and offers.
Building B,No.6 Xingzhi Road,Nanjing Economic and Technological Development Zone
Copyright © 2026 Farmasino Medical Co.,Ltd. All rights reserved. - Privacy Policy
EN
